BioSpace News Archive

BERG LLC yesterday presented findings that reveal potential biomarkers of disease activity in Systemic Lupus Erythematosus (SLE) in an oral presentation at the 2018 American College of Rheumatology and Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting in Chicago.

Horizon Pharma plc (Nasdaq: HZNP) today announced multiple presentations showing that people who have undergone a kidney transplant experience higher rates of uncontrolled gout compared to other renal disease patients, and mortality rates were higher in kidney transplant recipients diagnosed with gout.

“We were inspired by a girl who had a cracked and rotted front tooth. She could not afford to have the tooth pulled and desired a product that would snap atop her tooth with a normal appearance,” said inventors from Sun Valley, Calif. “This inspired us to develop a quick fix for a temporary attractive smile.”

Health Canada officials to hold a media technical briefing on the Assisted Human Reproduction Act.

Taiho Oncology, Inc. today announced that the United States Food and Drug Administration (FDA) has accepted and granted priority review for the supplemental New Drug Application (sNDA) for LONSURF® (trifluridine/tipiracil, TAS-102) as a treatment for patients with previously treated, advanced or metastatic gastric adenocarcinoma, including cancer of the gastroesophageal junction.

Dr. Robert Sackstein has been appointed dean of Florida International University’s Herbert Wertheim College of Medicine (HWCOM) and senior vice president for health affairs.

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced that it will present data from ATHENA, its global natural history of disease study for Alport syndrome

PricewaterhouseCoopers Inc., LIT, in its capacity as the court-appointed Monitor (in such capacity, the “Monitor”) of BioAmber Inc. (OTCPK: BIOAQ), BioAmber Canada Inc., and BioAmber Sarnia Inc. (collectively, the “Company”) in their proceedings under the Companies Creditors’ Arrangement Act, R.S.C. 1985, c. C-36, as amended (the “CCAA”), provides the following update on the Company’s liquidation process.

Enrollment completed in E2112; PFS not statistically significant; trial continues as planned having passed 3rd interim analysis for OS with additional planned OS analyses every 6 months

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the company’s Board of Directors has declared a cash dividend of $0.57 per share of common stock for the fourth quarter of 2018.